In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|
In: European Heart Journal, 2011, vol. 32, no. 22, p. 2748-2757
|
|
In: Herz Kardiovaskuläre Erkrankungen, 2007, vol. 32, no. 4, p. 296-300
|
In: European Journal of Cardio-Thoracic Surgery, 2015, vol. 47, no. 5, p. 860-861
|
In: European Heart Journal, 2013, vol. 34, no. 18, p. 1375-1383
|
In: Herz Kardiovaskuläre Erkrankungen, 2007, vol. 32, no. 4, p. 301-306
|
In: Herz Kardiovaskuläre Erkrankungen, 2005, vol. 30, no. 3, p. 189-196
|
In: Archives of Cardiovascular Diseases, 2012, vol. 105, no. 11, p. 587–592
BackgroundThe salt linked to the clopidogrel molecule in generic preparations is suspected to affect its clinical efficacy. There is a lack of information about inhibition of platelet reactivity by generic preparations.AimsTo compare the effect of original clopidogrel (clopidogrel bisulphate [Plavix®]), generic clopidogrel preparations (clopidogrel hydrochloride...
|
In: European Heart Journal, 2011, vol. 32, no. 24, p. 3115-3127
|